DALE CASE: Open Payments
NPI 1528511359 · LIMA, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$904 in 49 payments from 17 companies in 2025. Trend: 2023 $479 · 2024 $1,019 · 2025 $904
Food & beverage: $904
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $263 |
| ABBVIE INC. | 8 | $135 |
| Otsuka America Pharmaceutical, Inc. | 5 | $90 |
| Lilly USA, LLC | 4 | $76 |
| Aimmune Therapeutics, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Alkermes, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $27 |
Products named: REXULTI, AIRSUPRA, VRAYLAR, FARXIGA, MOUNJARO, BREZTRI, ZENPEP, CAPLYTA.
Industry payments across OH — which companies pay providers there.
